Market Closed -
Other stock markets
|
After market 05:20:21 pm | |||
169.4 USD | +0.50% | 170.1 | +0.40% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.32% | 298B | |
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+5.90% | 164B | |
-0.73% | 163B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc., Q1 2024 Earnings Call, Apr 26, 2024